Categories
Archives
Receive Email Updates
-
-
-
Certified Licensing Professionals, Inc., 2021 
Disclaimer
This blog, Patents4Life, does not contain legal advice and is for informational purposes only. Its publication does not create an attorney-client relationship nor is it a solicitation for business. This is the personal blog of Warren Woessner and does not reflect the views of Schwegman Lundberg & Woessner, or any of its attorneys or staff. To the best of his ability, the Author provides current and accurate information at the time of each post, however, readers should check for current information and accuracy.
-
- About Me
Warren D. Woessner
Pages
Archives
Tag Archives: USPTO
Patents4Life is Six Years Old this Month. Happy Birthday to Us!
Six years ago, In re Kubin caused a flurry of concern among biotech practitioners, and a short article on this decision was the first post on Patents4Life. That was a pretty big “story” at the time but we all had … Continue reading
Posted in Miscellaneous
Tagged Amgen, biotechnology, FDA, Kimble v. Marvell, Nautilus, Patent Law, s. 101, Teva v. Sandoz, Tharasense, USPTO
4 Comments
Section 101 at the AIPLA Midwinter Meeting
Although the primary focus of this four day meeting was licensing, there were two simultaneous tracks that contained at least a section of the effect/uncertainty of the recent judicial decisions and PTO Guidelines on licensor/licensee relationships. (I spoke at one … Continue reading
Posted in Patent Eligible Subject Matter
Tagged AIPLA, biotechnology, biotechnology law, intellectual property, ip, USPTO, Warren Woessner
Leave a comment
The “Top Ten” IP Stories of 2014 (Most “Definitely”)
I don’t think I can recall a more action-packed year for intellectual property law in my career, much less during the almost six years that I have been writing this blog. I am trying to write this while in transit, … Continue reading
Mayo Meet Alice Meet Myriad – Fed. Cir. Appreciates “Abstract Art”
On December 20th, a panel of the Fed. Cir. of Judges Dyk, Clevinger and Prost – Dyk writing – found that six claims in Myriad’s dwindling arsenal of BRACA1 and 2 patents were invalid as claiming non-statutory subject matter. (University … Continue reading